Dr Reddy's Stock Heads for Worst Day in 3 Years on Semaglutide Supply Issues

India-based pharmaceutical company Dr. Reddy's Laboratories is experiencing a sharp decline in its stock price due to disruptions in semaglutide supply. According to Reuters, the company is heading for its worst daily performance in three years. This has heightened investor concerns about the company's revenue expectations. Semaglutide, a drug used in the treatment of diabetes and obesity, holds a significant place in Dr. Reddy's portfolio. The supply chain disruptions are expected to negatively impact the company's revenues from this product. Market analysts note that this development could pressure Dr. Reddy's short-term financial performance. As the stock continues to lose value in intraday trading, a notable increase in trading volume is observed. Investors are focused on how quickly the company can resolve the supply issues and the impact on annual profit margins. Dr. Reddy's is expected to make an official statement on the matter. Experts indicate that competition in the semaglutide market is intense and that supply problems could lead to a loss of market share for the company. However, it is also assessed that Dr. Reddy's can overcome this challenge thanks to its strong R&D infrastructure and diversified product portfolio. The market will closely monitor the company's performance in the coming quarters. This is not investment advice.